KALA BIO, Inc. — Director's Dealing 2022

Jun 30, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2022-06-27

Reporting Person: Bazemore Todd (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-27	Common Stock	S	3092	$0.37	Disposed	115499	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	42	Indirect

Footnotes

F1: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.

F2: Includes 58,834 unvested RSUs.